Placebo once daily

DRUG3 trials

Sponsors

GlaxoSmithKline, AstraZeneca, Novartis Pharmaceuticals

Conditions

AsthmaEfficacyPulmonary Disease, Chronic ObstructiveSafety

Phase 2

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPD

CompletedNCT01039675

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2010-01-01End: 2010-04-20Updated: 2017-11-08

A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma

CompletedNCT02479412

AstraZenecaAsthma, Efficacy, Safety

Start: 2015-06-25End: 2016-02-08Updated: 2018-02-15

Phase 3

Systemic Corticosteroids Avoidance Study in Severe Asthma Patients

TerminatedNCT03629249

Novartis PharmaceuticalsAsthma

Start: 2018-12-13End: 2020-02-06Updated: 2021-10-11

Related Papers

Efficacy and safety of AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, in patients with asthma: a phase 2a randomized, double blind, placebo-controlled crossover trial

Respiratory Research2019-02-1826 citations